A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533

Clinical Lung Cancer

Volumn 16, Issue 5, 2015, Pages 340-347

  Wozniak, Antoinette J ^a   Moon, James ^b   Thomas, Charles R ^c   Kelly, Karen ^d   Mack, Philip C ^d   Gaspar, Laurie E ^e   Raben, David ^e   Fitzgerald, Thomas J ^f   Pandya, Kishan J ^g   Gandara, David R ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f Quality Assurance Review Center   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Cisplatin etoposide; Concurrent chemoradiotherapy; Locally advanced NSCLC; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; ELECTROLYTE; ETOPOSIDE; ANTINEOPLASTIC AGENT; TAXOID;

ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DRUG EFFICACY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HEMOPTYSIS; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PNEUMONIA; RADIATION DOSE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; CARCINOMA, NON-SMALL-CELL LUNG; COHORT ANALYSIS; LUNG NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PILOT STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; TAXOIDS;

EID: 84941422862     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.12.014     Document Type: Article

References (27)

1. K. Furuse, M. Fukuoka, M. Kawahara, and et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699
2. W.J. Curran Jr., R. Paulus, C.J. Langer, and et al. Sequential vs. concurrent chemoradiation for stage III non-small-cell lung cancer: randomized phase III RTOG 9410 J Natl Cancer Inst 103 2011 1452 1460
3. K.S. Albain, J.J. Crowley, A.T. Turrisi, and et al. Concurrent cisplatin, etoposide plus radiotherapy for pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study (S9019) J Clin Oncol 20 2002 3454 3460
4. D.R. Gandara, K. Chansky, K.S. Albain, and et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group study S9504 J Clin Oncol 21 2003 2004 2010
5. D.R. Gandara, K. Chansky, K.S. Albain, and et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group study (S9504) Clin Lung Cancer 8 2006 116 121
6. K. Kelly, K. Chansky, L.E. Gaspar, and et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
7. D.R. Gandara, E. Vokes, M. Green, and et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial J Clin Oncol 18 2000 131 135
8. F.A. Shepherd, J. Dancey, R. Ramlau, and et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
9. J. Folkman, and Y. Shing Angiogenesis J Biol Chem 267 1992 10931 10934
10. M. Toi, T. Matsumoto, and H. Bando Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications Lancet Oncol 2 2001 667 673
11. A. Yuan, C.J. Yu, S.H. Kuo, and et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer J Clin Oncol 19 2001 432 441
12. E. Cababe, and H. Wakelee Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors Curr Treat Options Oncol 8 2007 15 27
13. D.H. Johnson, L. Fehrenbacher, W.F. Novotny, and et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2189
14. A. Sandler, R. Gray, M.C. Perry, and et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
15. L. Geng, E. Donnelly, G. McMahon, and et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy Cancer Res 61 2001 2413 2419
16. D.H. Gorski, M.A. Beckett, N.T. Jaskowiak, and et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378
17. K.J. Williams, B.A. Telfer, S. Brave, and et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity Clin Cancer Res 10 2004 8587 8593
18. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
19. R. Brookmeyer, and J. Crowley A confidence interval for the median survival time Biometrics 38 1982 29 41
20. N. Hanna, M. Neubauer, C. Yiannoutsos, and et al. Phase III study of cisplatin, etoposide, and concurrent radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology J Clin Oncol 26 2008 5755 5760
21. A.B. Sandler, J.H. Schiller, R. Gray, and et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab J Clin Oncol 27 2009 1405 1412
22. A. Fairchild, K. Harris, E. Barnes, and et al. Palliative thoracic radiotherapy for lung cancer: a systemic review J Clin Oncol 26 2008 4001 4011
23. Y.H. Kim, E.Y. Kim, H.J. Ban, and et al. Risk factors for fatal hemoptysis after concurrent chemoradiation therapy in patients with non-small-cell lung carcinoma Chonnam Med J 46 2010 19 24
24. M.A. Socinski, T.E. Stinchcombe, D.T. Moore, and et al. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial J Clin Oncol 30 2012 3953 3959
25. J.F. Patton, D.R. Spigel, F.A. Greco, and et al. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small-cell lung cancer (LS-SCLC): update of a phase II trial of the Minnie Pearl Cancer Research Network (abstract 7085) J Clin Oncol 24 2006 385a
26. D.R. Spigel, J.D. Hainsworth, D.A. Yardley, and et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab J Clin Oncol 28 2009 43 48
27. M.A. Socinski, D.E. Morris, J.S. Halle, and et al. Induction and concurrent chemotherapy with high dose conformal radiation in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose escalation phase I/II trial J Clin Oncol 22 2004 4341 4350